Versatile virus-like particle carrier for epitope based vaccines - Wikidata - awgldk - TriplyDB

Versatile virus-like particle carrier for epitope based vaccines

Versatile virus-like particle carrier for epitope based vaccines

http://www.wikidata.org/entity/Q28748358

about

sameAs

Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers.Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus The S. aureus 4-oxalocrotonate tautomerase SAR1376 enhances immune responses when fused to several antigens.Influenza A viruses: why focusing on M2e-based universal vaccines.Sublingual immunization with M2-based vaccine induces broad protective immunity against influenza.Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice.Development of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway.Titrating T-cell epitopes within self-assembled vaccines optimizes CD4+ helper T cell and antibody outputs Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization.Bacterial superglue enables easy development of efficient virus-like particle based vaccines.A novel M2e based flu vaccine formulation for dogs.Antigenic analysis of monoclonal antibodies against different epitopes of σB protein of avian reovirus.A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1 Early Transcriptome Signatures from Immunized Mouse Dendritic Cells Predict Late Vaccine-Induced T-Cell Responses.A Conserved Epitope Mapped with a Monoclonal Antibody against the VP3 Protein of Goose Parvovirus by Using Peptide Screening and Phage Display Approaches.Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery.Display of single-chain variable fragments on bacteriophage MS2 virus-like particles.Engineering virus-like particles as vaccine platforms Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design.Towards artificial metallonucleases for gene therapy: recent advances and new perspectives.Hepatitis B core-based virus-like particles to present heterologous epitopes.Advances and challenges in the development and production of effective plant-based influenza vaccines.The application of virus-like particles as vaccines and biological vehicles.Different applications of virus-like particles in biology and medicine: Vaccination and delivery systems.Virus-based nanoparticles as platform technologies for modern vaccines.Immunocontraception: Filamentous Bacteriophage as a Platform for Vaccine Development.Mapping a Type-specific Epitope by Monoclonal Antibody against VP3 Protein of Duck Hepatitis A Type 1 Virus.Evaluation of lumazine synthase from Bacillus anthracis as a presentation platform for polyvalent antigen display.Adjuvant effect of B domain of staphyloccocal protein A displayed on the surface of hepatitis B virus capsid.Target highlights from the first post-PSI CASP experiment (CASP12, May-August 2016).Mosaic RNA phage VLPs carrying domain III of the West Nile virus E protein.Yeast-expressed bacteriophage-like particles for the packaging of nanomaterials.The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation.Universal influenza vaccine: the holy grail?Effects of pre-existing anti-carrier immunity and antigenic element multiplicity on efficacy of a modular virus-like particle vaccine.Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.Potato virus Y-like particles as a new carrier for the presentation of foreign protein stretches.Intranasal vaccination with M2e5x virus-like particles induces humoral and cellular immune responses conferring cross-protection against heterosubtypic influenza viruses.

P2860

Q26830028-C96BBF89-A33C-4EAE-94BF-AC4DD6E5A085 Q27003874-26EBCC55-165F-4BF7-921D-67CC13E20CE1 Q28280059-272E5373-0D65-40F3-BC75-A1153CFED59E Q29994694-51E65E3C-07D2-4C0F-B6F7-E4EC15BC4983 Q30396318-79CDA742-17F4-4F4E-BA16-1BF449C1E399 Q30410241-6E41E8A8-06EE-48AE-A66B-C945DBF6564C Q33876183-4836D990-001F-466B-B774-C0EBDCC5A874 Q34039347-6F165CEA-A490-4B1C-BBA1-E4EEB7909781 Q34472793-66BE0918-E51C-473D-938F-3EF3400F10E3 Q34490296-C256F4F6-833A-482E-B6EE-0B3599C605B9 Q34509612-816F9395-8CBA-4A20-8250-14578F8C3FE2 Q34523734-2876D4E6-F4F1-4FB7-B4E3-1FF13BB2E64C Q35009732-231435C0-8EC6-4EA1-AE59-28C9799D4E5B Q35060573-C8998C56-B3E9-4C27-A8D6-0B47B9B1576B Q35940744-775C4428-14A8-4B1E-94F2-2603A7F23F04 Q35964579-872F487C-5F83-4D68-81D0-29FF7633A8CA Q36020868-D65CCB18-CD8B-4D43-B6A4-57BE333EBD61 Q36155247-B14C92F2-6F14-4026-87B4-FDCBE9C0A8FC Q36279158-30A3D0F2-9855-47B1-93C0-9BDB99B167F9 Q37172342-7D3ABFE2-9363-4CB1-A63F-0700A14ADE96 Q37792984-3C93AAE3-5D35-438F-A50A-D9DA5D3B8A6B Q37948867-C9104E2F-C446-43A9-98C8-A84CFDEFA24E Q38081969-41651E65-DD12-4A1B-9CCA-1E39E5150941 Q38285425-CBE6E20E-B055-4199-A50D-6ED77D0BAE01 Q38603912-9BE56E37-13B2-4B46-9902-D66610C9D305 Q38618258-CF43D8C2-2B00-4751-87D9-3FE3F0E2E2F7 Q38702017-B3E3A1E6-6FAD-4ED8-B846-CF8317860BFC Q40044131-93573784-5257-4433-BE61-E703865BBC37 Q40052216-418BA689-AC47-4786-A182-09F22EC2C87F Q40122953-73A73A95-4C45-433D-AF4F-4D59E1071E6E Q41534162-095C6134-80E1-40EC-A354-3C8511A2E098 Q41928117-42816116-C386-4502-A722-BCD43DCB9984 Q42235222-5C02DA24-0F23-4F3E-81B5-176A5F52E31D Q42283846-55BBA1CC-888F-4EFB-BAE7-1E0F3C7AB1F5 Q42926219-27189CC8-9A86-47D1-B7C1-B7347EF53867 Q43692141-2DEDF4B1-0CB5-4588-B72A-F18DDEAECC8A Q45157613-1E66212F-85B0-401B-93DB-D6DFC8092C5B Q45358078-4CC462E8-7FAE-4B7F-AF1E-8020D2A6453D Q45361083-42BBB5B2-5103-47D3-A24C-F3DDB7E65AFD Q47555220-896272C4-9836-44F5-B07F-9AC6DB37794E

P2860

Versatile virus-like particle carrier for epitope based vaccines

http://www.wikidata.org/entity/Q28748358

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Versatile virus-like particle carrier for epitope based vaccines

@ast

Versatile virus-like particle carrier for epitope based vaccines

@en

Versatile virus-like particle carrier for epitope based vaccines

@nl

type

label

Versatile virus-like particle carrier for epitope based vaccines

@ast

Versatile virus-like particle carrier for epitope based vaccines

@en

Versatile virus-like particle carrier for epitope based vaccines

@nl

prefLabel

Versatile virus-like particle carrier for epitope based vaccines

@ast

Versatile virus-like particle carrier for epitope based vaccines

@en

Versatile virus-like particle carrier for epitope based vaccines

@nl

P1433

Q28748358-72E0AA28-4C34-4F70-990D-AFA61B302853

P1476

Q28748358-EC5115DC-0F8A-4461-8ABF-F9DB30FDEBED

P2093

Q28748358-123E7462-F17C-40EA-A79F-12CBC0570675

Q28748358-242C35F5-4A0B-41ED-AE49-F102F60A8172

Q28748358-3BF7C8E4-13EF-4B45-AB97-1F1FF306D7BC

Q28748358-5CCD89F5-4F2F-49B6-B4E9-C459ED5CB8DA

Q28748358-6BAABE89-7433-4A36-BA23-7FADAF5E59D3

Q28748358-8E0709ED-E536-41AF-99DA-EC948A2CFA15

Q28748358-92E39ACE-0129-4A85-984E-540FCA10F777

Q28748358-B5BE1B1F-06A2-4164-B3AF-15E54211B303

Q28748358-D72DFC2B-4BF4-4F46-B450-ACD971507D68

Q28748358-F87BAF18-CC89-4EAF-91B6-F35E2FB2E7FB

P2860

Q28748358-00C5E798-3F56-4B8F-94A2-1CA671386829

Q28748358-00C8515D-0B99-41A0-9658-FF1BBA0C48DD

Q28748358-026AA884-A52F-4207-955A-E994932E2A82

Q28748358-1BAE9602-68CE-48C2-A8AC-2FA0F0E31070

Q28748358-213D8913-1382-4DDD-9025-070A5CF33226

Q28748358-216B0A8B-C960-411F-B00D-9C7DF5C2934A

Q28748358-244D4D1E-C2CF-4CC6-BE8E-D26E511E734F

Q28748358-3B17E698-07DF-4AFA-BE1D-7BC8B72A9481

Q28748358-4640191A-F71F-4204-A8EF-045C4526E265

Q28748358-475A3CFF-FAFC-4F94-A735-1E14248C3A86

P304

Q28748358-6E2E17CB-5D10-49AB-884B-36125B8563ED

P31

Q28748358-9B347A52-46C8-4DAD-8568-F2F282780359

P3181

Q28748358-6CB044F3-AB63-49BA-B00B-0762467147E9

P356

Q28748358-39161B1B-82F1-4D60-BEDD-74EF97C5C99E

P407

Q28748358-6CFED32A-4470-43F0-BD6A-FC03025FF12A

P433

Q28748358-4EBD92B0-0B4D-4375-84F8-C03260B862D1

P478

Q28748358-AFBA46AA-FFA5-4B5B-B4F1-32F54EED3F2D

P577

Q28748358-EF3FA16D-E40B-43BE-AE3A-E70FDFCBE2E7

P5875

Q28748358-23593BED-3497-458D-BDA5-4920712742F5

P698

Q28748358-D25B6CF7-B11E-4ADD-A817-707A2224C4D7

P932

Q28748358-B45E2FF3-3DF7-4484-9355-47ECDAD184A5

P3181

P356

JOURNAL.PONE.0009809

P1433

P1476

Versatile virus-like particle carrier for epitope based vaccines

@en

P2093

Alain C Tissot

http://www.w3.org/2001/XMLSchema#string

Edwin Meijerink

http://www.w3.org/2001/XMLSchema#string

Gary T Jennings

http://www.w3.org/2001/XMLSchema#string

Indulis Cielens

http://www.w3.org/2001/XMLSchema#string

Martin F Bachmann

http://www.w3.org/2001/XMLSchema#string

Nicole Schmitz

http://www.w3.org/2001/XMLSchema#string

Paul Pumpens

http://www.w3.org/2001/XMLSchema#string

Philippe Saudan

http://www.w3.org/2001/XMLSchema#string

Regina Renhofa

http://www.w3.org/2001/XMLSchema#string

Velta Ose

http://www.w3.org/2001/XMLSchema#string

P2860

Vaccination against GIP for the treatment of obesity

Structure determination of bacteriophage PP7 from Pseudomonas aeruginosa: from poor data to a good map

A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity

A vaccine against nicotine for smoking cessation: a randomized controlled trial

The role of B cells in acute and chronic infections.

A universal influenza A vaccine based on the extracellular domain of the M2 protein.

A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.

HBV core particles as a carrier for B cell/T cell epitopes.

Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study.

On natural and artificial vaccinations.

P304

e9809

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1562043

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0009809

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42639964

http://www.w3.org/2001/XMLSchema#string

P698

20352110

http://www.w3.org/2001/XMLSchema#string

P932

2843720

http://www.w3.org/2001/XMLSchema#string